Shareholders vote on Alcon’s blockbuster acquisition proposal for Staar Surgical; the FDA responds to Outlook’s latest BLA submission for wet AMD drug Lytenava; and the FDA approves an interchangeable biosimilar to Lucentis.
Learn more about your ad choices. Visit megaphone.fm/adchoices
